Chinese Journal of Pharmacovigilance ›› 2024, Vol. 21 ›› Issue (4): 428-434.
DOI: 10.19803/j.1672-8629.20230532
Previous Articles Next Articles
ZHOU Yue1, LIU Shuo2, SONG Haibo2
Received:
2023-08-30
Online:
2024-04-15
Published:
2024-04-18
CLC Number:
ZHOU Yue, LIU Shuo, SONG Haibo. Roles of licensed pharmacists in drug classification management[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 428-434.
[1] ZHANG Q, LIN F.Problems and countermeasures in drug classification management in China[J]. China Medical Review(中国医药导报), 2010, 7(19): 177-178. [2] NMPA. Measures for Classified Administration of Prescription Drugs and Non-prescription Drugs (Trial)[EB/OL]. (1999-06-18)[2023-08-04]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_12152ec09ea843629031a1850c688a2c.html. [3] ZHOU Y, XU L.Thoughts and suggestions on legislation of licensed pharmacists in China[J]. Chinese Journal of Rational Drug Use(中国合理用药探索), 2021, 18(1): 29-33. [4] NMPA. Notice of the department of human resources and social security of the state drug administration on the issuance of the provisions of the professional qualification system for licensed pharmacists and the implementation measures of the professional qualification examination for licensed pharmacists[EB/OL]. (2021-09-30)[2023-08-04]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20190320161601446.html. [5] JIANG H, SHU YC, JIANG YZ, et al.Existing problems and countermeasures of drug classification management in drug retail enterprises[J]. China Pharmaceutical Industry(中国药业), 2022, 31(14): 30-34. [6] CHEN B, WENG JY, KIM L.The influence of the drug classification management system for TCM pharmacy drugs management[J]. Journal of Traditional Chinese Medicine Management Journal(中医药管理杂志), 2021, 29(18): 99-100. [7] MENG LY.Analysis of the influence of drug classification management system on hospital pharmacy department[J]. China Prescription Drugs(中国处方药), 2020, 18(5): 31-32. [8] NMPA. Drug Administration Law of the People's Republic of China [EB/OL]. (2019-08-27)[2023-08-17]. https://www.nmpa.gov.cn/xxgk/fgwj/flxzhfg/20190827083801685.html. [9] NMPA. Regulations for the Implementation of the Drug Administration Law of the People's Republic of China[EB/OL]. (2019-03-02) [2023-08-17]. https://www.nmpa.gov.cn/xxgk/fgwj/flxzhfg/20230328161255114.html. [10] State Administration for Market Regulation. Measures for the Administration of Drug Registration[EB/OL]. (2020-01-22)[2023-08-17]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_3275cb2a929d4c34ac8c0421b2a9c257.html. [11] NMPA. Measures for the Supervision and Administration of Drug Circulation[EB/OL].(2007-01-31)[2023-08-17]. https://www.nmpa.gov.cn/xxgk/fgwj/nbmgzh/20070131010101619.html. [12] State Administration for Market Regulation. Good Quality Control of Drug trade[EB/OL]. (2015-06-25)[2023-08-17]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_bc07ffdb7a1c4e46be371ac5a4a65f9c.html. [13] NMPA. Regulations on the administration of drug instructions and labels[EB/OL]. (2006-03-15)[2023-08-17]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_b1a64fa4b9314ecabadf3c6662b70c48.html. [14] State Administration for Industry and Commerce. Standards for examination and publication of drug advertisements[EB/OL]. (2007-03-03)[2023-08-17]. https://www.nmpa.gov.cn/yaopin/ypfgwj/ypfgbmgzh/20070303010101471.html. [15] NMPA, Ministry of Health, National Administration of Traditional Chinese Medicine, et al. Notice on several opinions on the implemen-tation of classified management of prescription and non-prescription drugs in China[EB/OL].(1999-04-19)[2023-08-21]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/19990419010101154.html. [16] NMPA. Notice on doing a good job in the administration of drug classification in2001[EB/OL]. (2001-07-02)[2023-08-21]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20010702010101262.html. [17] NMPA. Notice on the Issuance of Provisional Provisions on the Circulation of Prescription Drugs and Non-prescription Drugs[EB/OL].(1999-12-28)[2023-08-21]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/19991228010101969.html. [18] GUO Y, WANG JB, ZHANG WY.Comparison and enlightenment of drug classification management systems in China and the United States[J]. China Pharmaceutical Affairs(中国药事), 2010, 24(6): 612-614. [19] LI YY.Introduction to German drug classification management[J]. Chinese Pharmacy(中国药房), 2008, 19(22): 1757-1758. [20] XU G, LUO WH, SONG HH.Research and reference on classification management system of prescription drugs and non-prescription drugs in Canada[J]. Chinese Pharmacy(中国药房), 2023, 34(1): 1-6. [21] CHEN Y, ZHOU YX, SHAO R, et al.The practice of expanding the responsibilities of community pharmacists in the United States, Britain and Australia and its implications for China[J]. Chinese Pharmacy(中国药房), 2017, 28(34): 4758-4762. [22] YANG LY, ZHAO ZG.Overview of pharmacies in Germany and implications for pharmacies in China[J]. Drug Evaluation(药品评价), 2012, 9(26): 10-14. [23] XU XY, ZHANG KL.Training of pharmacists in Canada and its implications for China[J]. Medical Review(医药导报), 2015, 34(5): 701-704. [24] NMPA. Notice on the implementation of classified management of prescription drugs and non-prescription drugs[EB/OL]. (2005-07-02)[2023-08-22]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20050812010101140.html. [25] JIANG H, SHU YC, JIANG YZ, et al.Existing problems and countermeasures of drug classification management in drug retail enterprises[J]. China Pharmaceutical Industry(中国药业), 2022, 31(14): 30-34. [26] NMPA. Notice of the State Drug Administration on regulating the use of licensed pharmacists in drug retail enterprises[EB/OL]. (2020-11-20)[2023-08-22]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjzh/20201120180907191.html. [27] Pharmacists Online. Because of the“drug matters”problem, a pharmacy compensated nearly 200,000[EB/OL]. (2020-11-20)[2023-08-22]. https://mp.weixin.qq.com/s/sBmtlRGPZIE8Cw_4a3Quxg. [28] CCLP of NMPA. December 2014 - December 2022 and June 2023 National licensed pharmacists registration status[EB/OL].(2000-11-20)[2023-08-22]. http://www.cqlp.org/info/infoxlb.aspx?page=1&infox=1000710001. [29] CCLP OF NMPA. 2014-2022 Results of the national Licensed Pharmacist qualification examination[EB/OL]. (2000-11-20) [2023-08-22]. http://www.cqlp.org/info/infoxlb.aspx?page=1&infox=1000310001. [30] State Food and Drug Administration Licensed Pharmacist Qualification Certification Center. Report on the Development of Licensed Pharmacists in China(中国执业药师发展报告)[M]. Beijing: China Medical Science and Technology Press, 2014. [31] NMPA. National pharmacist confirmation registration list[EB/OL]. (2016-12-30)[2023-8-22]. http://cqlp.org/info/link_gscyys.html. [32] NMPA. Statistical Bulletin on the Development of China's health Undertakings in 2021[EB/OL]. (2022-07-12)[2023-08-22]. http://www.nhc.gov.cn/guihuaxxs/s3586s/202207/51b55216c2154332a660157abf28b09d.shtml. [33] NMPA.The 4th“Most Beautiful Pharmacists Around”List (sorted by surname strokes)The 4th“Most Beautiful Pharmacists Around”List (sorted by surname strokes)[EB/OL].(2023-04-28)[2023-08-22]. https://www.nmpa.gov.cn/zwgk/rshxx/zhyyshgl/20230428144557122.html. [34] ZHOU Y, LI ZH, XIE GL, et al.Report on the development of licensed pharmacists in retail pharmacies[J]. China Food and Drug Regulation(中国食品药品监管), 2021(4): 88-93. [35] JIANG H, SHU YC, JIANG YZ, et al.Existing problems and countermeasures of drug classification management in drug retail enterprises[J]. China Pharmaceutical Industry(中国药业), 2022, 31(14): 30-34. [36] WU P, YANG SM. Pharmaceutical Management(药事管理学)[M]. 4th Ed. Beijing: People's Medical Publishing House, 2007: 307. [37] LIN DH, SUN KX, WANG AP.Thoughts on pharmaceutical education and training of licensed pharmacists[J]. Chinese Pharmacists(中国药师), 2008(11): 1382-1383. [38] LIU XP, ZHANG L.Discussion on the deficiencies and countermeasures of the current qualification system and examination methods for licensed pharmacists in China[J]. Chinese Journal of Rational Drug Use(中国合理用药探索), 2019, 19(10): 92-96. [39] WEN RR, XU L, ZHU WJ.Analysis and reflection on the pharmacy examination outline of the National Professional Qualification Examination for Licensed pharmacists[J]. Journal of Pharmaceutical Practice(药学实践杂志), 2022, 40(4): 383-386. [40] WEI CY, CHEN QM, AN J, et al.Investigation on the current situation and demand of pharmacists'competency based on the transformation of pharmaceutical care competency standards[J]. Chinese Journal of Medicine(中国药学杂志), 2019, 58(13): 1236-1244. [41] LI ZH, ZHOU Y, ZHANG TT.Investigation and analysis on the implementation of continuing education for licensed pharmacists[J]. China Medical Guide(中国医药导刊), 2022, 24(12): 1253-1257. [42] FENG YP.Training of professional quality of implantable pharmacists in pharmaceutical education in applied undergraduate colleges[J]. Journal of Southwest Normal University (Natural Science Edition)(西南师范大学学报), 2020(2): 132-136. [43] HONG L, ZHANG HX, YE H.Inspiration from the practical training system of Pharmacy students in some developed countries to China[J]. China Pharmaceutical Affairs(中国药事), 2018, 32(2): 190-194. [44] ZHOU J, FU MY, HUANG WJ, et al.Practice of situational simulation teaching on drug therapy management ability training for licensed pharmacists in social pharmacies[J]. Pharmacy Education(药学教育), 2023, 33(3): 64-67. [45] ZHU JW, JIANG R, SHAO R.Introduction and enlightenment of continuing education model for practicing pharmacists in Australia[J]. Chinese Pharmaceutical Industry(中国药业), 2022, 31(14): 14-19. [46] JIANG H, YANG JM.Research on countermeasures of pharmaceutical education based on the post competence of licensed pharmacists[J]. China Higher Medical Education(中国高等医学教育), 2019(1): 15-16. [47] NMPA. The Comprehensive Department of the State Drug Administration (SDA) publicly solicited opinions on the Pilot Work Programme for Reform of Drug Specifications for Aging and other documents[EB/OL]. (2023-06-29)[2023-08-23]. http://cqlp.org/info/link_gscyys.html. |
[1] | CAO Weiping, ZHANG Shichao, NI Xia, XIE Bing, WANG Xinzhi, XING Mengtao. Research Progress in Liver Injury Caused by Drugs Commonly Used during Pregnancy [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 528-531. |
[2] | YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281. |
[3] | LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42. |
[4] | SHAO Bo, ZHONG Lumiao, CHENG Yuzhu, DENG Hua, ZHU Lan. Risks to Safety of Yinhuang Oral Preparation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 84-87. |
[5] | YANG Yuxi, PEI Yusheng, LIU Tao, GAO Hua, CAI Tong. Current situation and reflection on limulus amebocyte lysate and recombinant reagents for testing [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 847-851. |
[6] | LI Fang, LONG Xiuying, BAI Na, WEI Jingxia. One case of severe systemic rash caused by atorvastatin calcium tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 939-942. |
[7] | HJELMSTRÖM Peter, BOWRING Geoffrey, YUE Qun-Ying, NORÉN G. Niklas. Methods for signal management using the global safety database VigiBase [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 836-840. |
[8] | QIU Jinghui, ZHOU Huziwei, CAO Ying, LI Wenpeng, WANG Shengfeng. Research progress on the influencing factors and intervention measures of opioid requirements [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 524-528. |
[9] | LIU Jie, ZHANG Jianmin, ZHANG Xiaomeng, LIU Fang, SONG Yuan, ZHONG Xuli. Management of risks to pediatric medications based on drug instructions of Chinese patent medicines in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 422-427. |
[10] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
[11] | SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414. |
[12] | LIU Xin, WANG Guojun. Pharmacological Care of Hypertension Due to Glucocorticoid Drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1303-1305. |
[13] | XU Meibao, PEI Yusheng, Liu Yadan, CHEN Chen, DU Ying, LI Wenlong, LIU Tao, CAI Tong. Comparative study of bacterial endotoxin capability verification project at China and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1113-1117. |
[14] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
[15] | YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||